<DOC>
	<DOC>NCT00387270</DOC>
	<brief_summary>This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.</brief_summary>
	<brief_title>Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36 Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale Clinical evidence of unstable medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Huntington's disease</keyword>
	<keyword>Dimebon</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>Phase 1-2a</keyword>
	<keyword>randomized</keyword>
	<keyword>controlled</keyword>
	<keyword>double-blind</keyword>
	<keyword>Unified Huntington's Disease Rating Scale</keyword>
</DOC>